A Double-blind, Placebo-controlled, Randomized, Single Ascending and Multiple Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Healthy Japanese Adult Male Participants
Latest Information Update: 13 Aug 2021
Price :
$35 *
At a glance
- Drugs Aticaprant (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Pharmaceutical KK
- 10 Aug 2021 Status changed from recruiting to completed.
- 10 May 2021 Status changed from not yet recruiting to recruiting.
- 16 Mar 2021 New trial record